参考文献/References:
[1] Glover AR, Gundara JS, Norlén O,et al. The pros and cons of prophylactic central neck dissection in papillary thyroid carcinoma[J].Gland Surg,2013,2(4):196-205. DOI: 10.3978/j.issn.2227-684X.2013.10.05.
[2] Smith VA, Sessions RB, Lentsch EJ. Cervical lymph node metastasis and papillary thyroid carcinoma: does the compartment involved affect survival Experience from the SEER database[J].J Surg Oncol,2012,106(4):357-362. DOI: 10.1002/jso.23090.
[3] Qu N, Zhang L, Ji QH, et al. Risk factors for central compartment lymph node metastasis in papillary thyroid microcarcinoma: A meta-analysis[J].World J Surg,2015,39(10):2459-2470. DOI: 10.1007/s00268-015-3108-3.
[4] Podnos YD, Smith D, Wagman LD,et al. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer[J].Am Surg,2005,71(9):731-734.
[5] Zaydfudim V, Feurer ID, Griffin MR,et al. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma[J].Surgery,2008,144(6):1070-1077; discussion 1077-1078. DOI 10.1016/j.surg.2008.08.034.
[6] Cranshaw IM, Carnaille B. Micrometastases in thyroid cancer. An important finding?[J]. Surg Oncol,2008,17(3):253-258.DOI 10.1016/j.suronc.2008.04.005.
[7] Cho SY, Lee TH, Ku YH, et al. Central lymph node metastasis in papillary thyroid microcarcinoma can be stratified according to the number, the size of metastatic foci, and the presence of desmoplasia[J].Surgery,2015,157(1):111-118.DOI:10.1016/j.surg.2014.05.023.
[8] Verburg FA, Mäder U, Tanase K,et al. Life expectancy is reduced in differentiated thyroid cancer patients ≥ 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients[J].J Clin Endocrinol Metab,2013,98(1):172-180. DOI: 10.1210/jc.2012-2458.
[9] Jeon MJ, Yoon JH, Han JM, et al. The prognostic value of the metastatic lymph node ratio and maximal metastatic tumor size in pathological N1a papillary thyroid carcinoma[J].Eur J Endocrinol,2013,168(2):219-225. DOI: 10.1530/EJE-12-0744.
[10] Schneider DF, Chen H, Sippel RS. Impact of lymph node ratio on survival in papillary thyroid cancer[J].Ann Surg Oncol,2013,20(6):1906-1911. DOI: 10.1245/s10434-012-2802-8.
[11] 中华医学会内分泌学分会, 中华医学会外科学分会内分泌学组, 中国抗癌协会头颈肿瘤专业委员会, 等. 甲状腺结节和分化型甲状腺癌诊治指南[J]. 中华内分泌代谢杂志, 2012, 28(10):779-797.
[12] Chan AC, Lang BH, Wong KP. The pros and cons of routine central compartment neck dissection for clinically nodal negative(cN0)papillary thyroid cancer[J].Gland Surg,2013,2(4):186-195. DOI: 10.3978/j.issn.2227-684X.2013.10.10.
[13] Zetoune T, Keutgen X, Buitrago D,et al. Prophylactic central neck dissection and local recurrence in papillary thyroid cancer: a meta-analysis[J]. Ann Surg Oncol, 2010,17(12):3287-3293. DOI: 10.1245/s10434-010-1137-6.
[14] Mulla M, Schulte KM. Central cervical lymph node metastases in papillary thyroid cancer: a systematic review of imaging-guided and prophylactic removal of the central compartment[J].Clin Endocrinol(Oxf),2012,76(1):131-136.DOI:10.1111/j.1365-2265.2011.04162.x.
[15] Yeh MW, Bauer AJ, Bernet VA,et al. American Thyroid Association statement on preoperative imaging for thyroid cancer surgery[J].Thyroid,2015,25(1):3-14.DOI:10.1089/thy.2014.0096.
[16] McLeod DS, Sawka AM, Cooper DS. Controversies in primary treatment of low-risk papillary thyroid cancer[J].Lancet,2013, 381(9871):1046-1057.DOI:10.1016/S0140-6736(12)62205-3.
[17] Perros P, Boelaert K, Colley S,et al. Guidelines for the management of thyroid cancer[J].Clin Endocrinol(Oxf),2014,81(Suppl 1):1-122. DOI: 10.1111/cen.12515.
[18] Xing M, Westra WH, Tufano RP,et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer[J].J Clin Endocrinol Metab,2005,90(12):6373-6379.
[19] Xing M, Alzahrani AS, Carson KA,et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer[J].JAMA,2013,309(14):1493-1501. DOI: 10.1001/jama.2013.3190.
[20] Howell GM, Nikiforova MN, Carty SE,et al. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer[J].Ann Surg Oncol,2013,20(1):47-52.DOI:10.1245/s10434-012-2611-0.
[21] Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer[J].Lancet,2013,381(9871):1058-1069.DOI:10.1016/S0140-6736(13)60109-9.
相似文献/References:
[1]于亚静,杨彩哲,刘明,等.BRAFV600E在甲状腺乳头状癌与桥本甲状腺炎相关性中的研究[J].国际内分泌代谢杂志,2014,(06):375.[doi:10.3760/cma.j.issn.1673-4157.2014.06.004]
Yu Yajing,Yang Caizhe,Liu ming,et al.Study of BRAFV600E in the correlation between papillary thyroid carcinoma and Hashimoto’s thyroiditis[J].International Journal of Endocrinology and Metabolism,2014,(04):375.[doi:10.3760/cma.j.issn.1673-4157.2014.06.004]
[2]周秦毅,陈隽,冯嘉麟,等.TM7SF4对人甲状腺乳头状癌细胞IHH-4
增殖、凋亡和侵袭的作用研究[J].国际内分泌代谢杂志,2016,36(04):241.[doi:10.3760/cma.j.issn.1673-4157.2016.04.08]
Zhou Qinyi,Chen Jun,Feng Jialin,et al.Effects of TM7SF4 on proliferation, apoptosis and invasion of human papillary thyroid cancer IHH-4 cells[J].International Journal of Endocrinology and Metabolism,2016,36(04):241.[doi:10.3760/cma.j.issn.1673-4157.2016.04.08]
[3]徐婷,吴丹,胡翠宁,等.甲状腺乳头状癌的淋巴结转移预测模型建立[J].国际内分泌代谢杂志,2021,41(06):596.[doi:10.3760/cma.j.cn121383-20200826-08042]
Xu Ting,Wu Dan,Hu Cuining,et al.Construction of a risk-scoring model to predict lymph node metastasis in papillary thyroid carcinoma[J].International Journal of Endocrinology and Metabolism,2021,41(04):596.[doi:10.3760/cma.j.cn121383-20200826-08042]
[4]周美岑,兰玲,邓微,等.MCPIP4诱导甲状腺乳头状癌细胞系TPC-1周期停滞的机制[J].国际内分泌代谢杂志,2023,43(02):86.[doi:10.3760/cma.j.cn121383-20210605-06008]
Zhou Meicen,Lan Ling,Deng Wei,et al.The mechanism of RNA binding protein MCPIP4 induces cell cycle arrest in papillary thyroid cancer[J].International Journal of Endocrinology and Metabolism,2023,43(04):86.[doi:10.3760/cma.j.cn121383-20210605-06008]